Merck KGaA to Relocate Its DeImmunisation Research From Scotland to U.S.
DeImmunisation(TM) technologies aimed at developing antibodies and other protein therapeutics with superior tolerability profiles will continue to be an important asset in the discovery and development of innovative biological drugs for Merck. In the future this activity will be performed exclusively at Merck's U.S. research center, EMD Lexigen, located in Billerica, near Boston, MA. An internal evaluation revealed that synergies can be expected from a full integration of these activities with the research for New Biologic Entities taking place at EMD Lexigen. In addition, contract DeImmunisation work for external customers will no longer be offered. Eighteen employees in Scotland will be affected by the consolidation and closure of the Aberdeen site.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous